Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD)

被引：6

作者：

Morita S. ^{[1
]}

Fukuhara S. ^{[1
]}

Akizawa T. ^{[2
]}

Asano Y. ^{[3
]}

Kurokawa K. ^{[4
]}

机构：

[1] Department of Epidemiology and Health Care Research, Kyoto University, Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Yoshidakonoe-cho

[2] Center of Blood Purification Therapy, Wakayama Medical School, Wakayama

[3] Department of Internal Medicine, Jichi Medical School, Sashima Red Cross Hospital, Tochigi

[4] Research Center for Advanced Science and Technology, University of Tokyo, Tokyo

来源：

Clinical and Experimental Nephrology | 2005年 / 9卷 / 3期

关键词：

Chronic kidney disease; Composite endpoint; Oral carbonaceous adsorbent; Randomized clinical trial;

D O I：

10.1007/s10157-005-0358-7

中图分类号：

学科分类号：

摘要：

Background. The number of patients with chronic kidney disease (CKD) in Japan is currently rising. Therefore, measures to control the progression of CKD from a predialysis condition to endstage renal failure are urgently required. We are conducting a clinical trial to investigate the efficacy of an oral carbonaceous adsorbent (Kremezin) in patients at the predialysis stage of progressive chronic kidney disease (the Carbonaceous oral Adsorbent's effectiveness on Progression of chronic Kidney Disease [CAP-KD] trial). Methods. A multidisciplinary treatment regimen, consisting of antihypertensive therapy (using an angiotensin-converting-enzyme inhibitor and/or an angiotensin II receptor blocker) and a low-protein diet is conventionally used to treat patients with kidney disease. To assess the efficacy of Kremezin in preventing the progression of CKD, we compare two groups of patients, receiving either conventional treatment alone or such treatment paired with Kremezin. The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel-group comparison clinical trial and will be conducted as a researcher-directed study. The primary endpoint of this study is the time to the first event of a composite endpoint, comprising the following: (1) a doubling of serum creatinine (sCr); (2) an increase in sCr level to 6.0mg/dl or more; (3) endstage renal disease (defined as that requiring dialysis or renal transplantation); and (4) death. Secondary endpoints are as follows: (1) variation in urinary protein; (2) changes in creatinine clearance rate; (3) changes in health-related quality of life; and (4) adverse events. The total number of patients (putative) in this trial will be 450, with 225 patients in each group. Enrollment will take place over 2 years, with a 1-year follow-up period. Results. As this is an ongoing trial, results are not yet available. Conclusions. We believe that the CAP-KD trial is a well-designed study that will provide internationally relevant evidence concerning the outcomes of treatment in Japanese patients with CKD. © Japanese Society of Nephrology 2005.

引用

页码：219 / 227

页数：8

共 18 条

[1]

An overview of regular dialysis treatment in Japan (as of 31 Dec 2001), Ther Apher Dial, 8, pp. 1-32, (2004)

[2]

Klahr S., Levey A.S., Beck G.J., Caggiula A.W., Hunsicker L., Kusek J.W., The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group, N Engl J Med, 330, pp. 877-84, (1994)

[3]

Effect of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study, J Am Soc Nephrol, 7, pp. 2616-26, (1996)

[4]

Effects of ramipril on cardiovascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, pp. 253-9, (2000)

[5]

Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M., Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients, Ann Intern Med, 118, pp. 577-81, (1993)

[6]

Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Research Group, N Engl J Med, 334, pp. 939-45, (1996)

[7]

Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, pp. 1857-63, (1997)

[8]

Brenner B.M., Cooper M.E., De Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, pp. 861-9, (2001)

[9]

Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes, N Engl J Med, 345, pp. 851-60, (2001)

[10]

Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, pp. 870-8, (2001)

← 1 2 →